ClinicalTrials.gg
CompletedNCT00636519Updated Mar 18, 2024

Botulism Antitoxin Effects on Paralysis Induced by Botulinum Neurotoxins in the EDB Muscle

A Phase 1 interventional study of Botulism Antitoxin Bivalent (Equine) Types A and B and Botulism Antitoxin Heptavalent (Equine) Types A-G in Healthy Volunteers, sponsored by Emergent BioSolutions. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-18.

Sponsored by Emergent BioSolutions · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The primary purpose of this study is:

  1. To evaluate the model determined by the ability of botulism antitoxin (bivalent, Aventis) to neutralize Botulinum toxin in the Extensor Digitorum Brevis model of muscle paralysis in Stage A.
  2. To assess the ability of botulism antitoxin (heptavalent, Cangene) to neutralize Botulinum toxin in the Extensor Digitorum Brevis model of muscle paralysis in Stage B.
Read the detailed description

Botulism is a rare disease; however Botulinum toxins (neurotoxins) may be used as biological weapon especially in the form of aerosol. Botulism is caused by neurotoxins that are produced by the obligate anaerobic, gram-positive, spore-forming bacterium Clostridium botulinum (1). C. botulinum produces 8 serologically distinct neurotoxins identified as serotypes A, B, C1, C2, D, E, F, and G (2).

Therapy for botulism includes supportive care and passive immunization with antitoxin. Antitoxin should be administered to patients with neurologic signs of botulism as soon as possible after clinical diagnosis (3). Botulism antitoxin is prepared from plasma obtained from horses that have been immunized with a specific subtype of botulism toxoid and toxin.

The BT-002 is an exploratory pharmacodynamic study that is being performed to evaluate the effect of Botulism Antitoxins in preventing paralysis of extensor digitorum brevis muscle following BOTOX®/ MYOBLOC® administration. This study will compare bivalent and heptavalent products to a placebo. Safety data will be collected.

NP-018 (heptavalent equine-derived botulinum antitoxin) is prepared from plasma obtained from horses that have been immunized with a specific subtype of botulinum toxoid and toxin. Each individual horse is immunized against a single botulinum toxin subtype. Plasma is pooled from horses that have been immunized with the same botulinum toxin subtype. For each antitoxin serotype (A-G), a despeciated product will be produced by pepsin digestion of the IgG monomer in the equine plasma, yielding predominantly F(ab')2 fragment. Following the formulation, the seven antitoxin serotypes will be blended into a heptavalent product and filled into single-use vials. '

This research study will be conducted in two stages - Stage A and Stage B. If enrolled in the Stage A of the study, the subject will have an equal chance of getting either bivalent botulism antitoxin or placebo. If enrolled in Stage B of the study, the subject will have an equal chance of getting heptavalent botulism antitoxin (NP-018) or placebo. The subject will be receiving injections of Botox and Myobloc on the next day after the antitoxin administration in the left and right foot respectively. The subject's participation in this study will be for maximum of 57 days.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Botulism Antitoxin,Heptavalent,Bivalent,EDB Muscle,Paralysis
03

In context

Lead sponsor

Emergent BioSolutions is the lead sponsor of 47 studies on the registry; 7 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 7 (64%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female
  • Age 18 - 55 years
  • Body-mass index 19-30
  • Normal and healthy as determined by medical history, physical examination, , NCS, vital signs and tests of liver, kidney and hematological functions
  • Adequate form of for female subjects

    • For women with -using hormonal contraception (oral, injectable or implant) continuously for 3 months prior to the start of the study and willing to continue to use hormonal contraception throughout the entire study. IUD inserted or use of condoms for at least 2 months prior to dosing
    • Other forms of contraception may be considered as adequate at physician's discretion
    • Surgically-sterilized female subjects
    • For female subjects who are , an FSH ≥ than 40 mIU/mL must be obtained. If the FSH is \< 40 mIU/mL the subject must agree to use an acceptable form of contraception (see above for acceptable forms of contraception)
  • Signed written

Exclusion criteria

Exclusion Criteria:

  • Previously injected with BOTOX®, BOTOX® COSMETIC or MYOBLOC®
  • Any known or documented Botulinum infection/intoxication
  • Any known or documented allergies to horses (e.g. rash, wheezing, rhinitis etc. after exposure to horses)
  • Any known or documented allergies to horse serum (observation of adverse events after treatment with any kind of product containing horse serum)
  • Any moderate or severe food allergies, seasonal allergies or hay fever requiring treatment with peroral or parenteral drug
  • Any known or documented to blood products derived from a human or equine source
  • Any known or documented hypersensitivity to albumin
  • Positive result for Botulism Antitoxin skin sensitivity testing
  • Any known or documented allergy to rubber, latex or plastic
  • Known acute or chronic moderate or severe asthma requiring treatment with peroral and / or parenteral immunosuppressive drugs
  • Previously diagnosed or currently suspected Multiple Sclerosis or other neuromuscular degenerative disorder
  • Previously diagnosed or currently suspected motor neuron disease
  • Previously or currently diagnosed peripheral neuropathy of lower extremities' nerves
  • Current infection of the skin / skin problems at the injection site (foot)
  • Scar tissue or tattoo of the skin over the extensor digitorum brevis muscles.
  • Previously diagnosed or currently suspected diabetes
  • Previously diagnosed or currently suspected coagulopathies
  • Previously diagnosed or currently suspected vasculitis
  • Current treatment or treatment in the past 7 days with aminoglycosides, clindamycin, quinolines or aminopyridine
  • Heavy smokers (>10 cigarettes/day)
  • History of, or suspected substance abuse (including alcohol) or failure of drug screen at screening or at baseline
  • Use of any product within the past 30 days (prior to screening)
  • Pregnancy or lactation
  • Positive serological test for diagnosis of infection, hepatitis, or hepatitis
  • Abnormal (based on principle investigator assessment) nerve conduction study (NCS) results
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Stage A

    Botulism Antitoxin Bivalent (Equine) Types A and B Vs. Placebo

    Biological: Botulism Antitoxin Bivalent (Equine) Types A and B

  • Experimental
    Stage B

    Botulism Antitoxin Heptavalent (Equine) Types A-G Vs. Placebo

    Biological: Botulism Antitoxin Heptavalent (Equine) Types A-G

Interventions

  • BiologicalBotulism Antitoxin Bivalent (Equine) Types A and B

    One vial of Botulism Antitoxin Bivalent(Equine) Types A and B (1:10 in saline) or an Equivalent Volume of Placebo on Day 0 in Stage A

  • BiologicalBotulism Antitoxin Heptavalent (Equine) Types A-G

    One vial of Heptavalent Botulism Antitoxin (1:10 in saline) or an Equivalent Volume of Placebo on Day 0 in Stage B

06

What researchers measure

Primary outcomes

  1. Nerve Conduction Study

    Time frame: Screening, Baseline (Day 0, -3 hrs), Day 1 (-1 hr), Day 3, Day 4, Day 7, Day 14, Day 21, Day 28 or Early Withdrawal

Secondary outcomes

  1. Hematology

    Time frame: Screening, Baseline (Day 0, -3 hr), Day 7, Day 14, Day 21, Day 28 or Early Withdrawal

  2. Blood Chemistry

    Time frame: Screening, Baseline (Day 0, -3 hr), Day 7, Day 14, Day 21, Day 28 or Early Withdrawal

  3. Urinalysis

    Time frame: Screening, Baseline (Day 0, -3 hr), Day 7, Day 14, Day 21, Day 28 or Early Withdrawal

  4. Serum anti-Botulism Antitoxin Reactivity

    Time frame: Baseline, Day 28 or Early Withdrawal

  5. Adverse Events

    Time frame: Day 0, Day 1( -1 hr), Day 1, Day 3, Day 4, Day 7, Day 14, Day 21, and Day 28 or Early Withdrawal

  6. Vital Signs

    Time frame: Screening, Day 0 (-3 hrs), Day 0, Day 1 (-1 hr), Day 1, Day 3, Day 4, Day 7, Day 14, Day 21, and Day 28 or Early Withdrawal

  7. Physical Examination

    Time frame: Screening, Baseline (Day 0, -3 hrs), Day 1 (-1 hr), Day 3, Day 4, Day 7, Day 21 and Day 28 or Early Withdrawal

  8. 12-lead ECG

    Time frame: Screening/ Day 28 or Early Withdrawal

07

Study locations

2 sites
  • Dr. Gordon Peterson
    Loma Linda, California 92354, United States
  • R. Richard Sloop, M. D.
    Yakima, Washington 98902, United States
08

References and documents

Publications

  • Benedetto AV. The cosmetic uses of Botulinum toxin type A. Int J Dermatol. 1999 Sep;38(9):641-55. doi: 10.1046/j.1365-4362.1999.00722.x. No abstract available. PubMed 10517680 ↗
  • Carruthers A, Carruthers J. Cosmetic uses of botulinum A exotoxin. Adv Dermatol. 1997;12:325-47; discussion 348. No abstract available. PubMed 8973746 ↗
  • Tacket CO, Shandera WX, Mann JM, Hargrett NT, Blake PA. Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am J Med. 1984 May;76(5):794-8. doi: 10.1016/0002-9343(84)90988-4. PubMed 6720725 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2008
First posted
Mar 14, 2008
Start
Feb 2008
Primary completionActual
Oct 2009
CompletionActual
Oct 2009
Last update
Mar 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00636519
Collaborators
Department of Health and Human Services
Responsible party
Sponsor
First posted
Mar 14, 2008
Start date
Feb 2008
Primary completion
Oct 2009
Completion
Oct 2009
Last update
Mar 18, 2024

Study contacts

Richard Sloop, M. D.
principal investigator · R. Richard Sloop, M. D.
Gordon Peterson, Dr.
principal investigator · Faculty Physicains & Surgeons of Loma Linda University School of Medicine, Department of Neurology

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion